Scarica l'app Stockscreener
143.67
22.84%
26.71
Pre-mercato:
142.51
-1.16
-0.81%
Precedente Chiudi:
$116.96
Aprire:
$141.5
Volume 24 ore:
2.67M
Relative Volume:
3.57
Capitalizzazione di mercato:
$8.41B
Reddito:
$507.44M
Utile/perdita netta:
$-187.69M
Rapporto P/E:
-43.92
EPS:
-3.271
Flusso di cassa netto:
$-39.06M
1 W Prestazione:
+18.86%
1M Prestazione:
+33.45%
6M Prestazione:
+63.13%
1 anno Prestazione:
+52.44%
Intervallo 1D:
$130.90
$145.50
Intervallo di 1 settimana:
$113.00
$145.50
Portata 52W:
$73.16
$145.50
Glaukos Corp Stock (GKOS) Company Profile
Nome
Glaukos Corp
Settore
Industria
Telefono
949-367-9600
Indirizzo
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corp
|
143.67 | 7.00B | 507.44M | -187.69M | -39.06M | -3.271 |
ABT
Abbott Laboratories
|
90.79 | 163.10B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
315.13 | 123.10B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
80.97 | 105.15B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.61 | 86.87B | 20.62B | 3.56B | 3.66B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.50 | 47.44B | 6.30B | 1.07B | 1.34B | 1.8406 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-27 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | Iniziato | Goldman | Buy |
| 2025-05-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-12-02 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Iniziato | Truist | Buy |
| 2023-11-08 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Iniziato | Mizuho | Neutral |
| 2022-12-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-14 | Ripresa | Stephens | Overweight |
| 2022-10-04 | Iniziato | Needham | Buy |
| 2022-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2022-02-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2021-11-03 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Aggiornamento | Citigroup | Sell → Neutral |
| 2020-12-09 | Iniziato | Oppenheimer | Perform |
| 2020-11-17 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Iniziato | Jefferies | Hold |
| 2020-03-05 | Iniziato | Citigroup | Sell |
| 2020-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Aggiornamento | Berenberg | Hold → Buy |
| 2019-12-12 | Downgrade | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Iniziato | BTIG Research | Neutral |
| 2018-08-30 | Iniziato | Berenberg | Hold |
| 2018-08-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Reiterato | Stifel | Hold |
| 2018-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Downgrade | Stifel | Buy → Hold |
| 2018-03-01 | Reiterato | Cantor Fitzgerald | Buy |
| 2017-03-02 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Aggiornamento | Stifel | Hold → Buy |
| 2016-10-27 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Glaukos Corp Borsa (GKOS) Ultime notizie
GKOS SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus
Glaukos Corp. Earnings Call Signals Growth Momentum - TipRanks
GKOS Maintained by Citigroup -- Price Target Raised to $140 - GuruFocus
GKOS Maintains Overweight Rating by JP Morgan -- Price Target Ra - GuruFocus
GKOS Maintained by Wells Fargo -- Price Target Raised to $138.00 - GuruFocus
Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook - Zacks Investment Research
Glaukos Stock Surges 18% on Record Q1 Sales Beat and Raised 2026 Outlook as iDose TR Demand Soars - International Business Times Australia
GKOS Maintained by BTIG -- Price Target Raised to $141.00 - GuruFocus
GKOS Maintained by Needham -- Price Target Raised to $136 - GuruFocus
Glaukos (GKOS) Rule 144: Fidelity lists 10,000‑share resale, insider trades - Stock Titan
Glaukos stock reaches 52-week high at $143.81 By Investing.com - Investing.com India
Glaukos Corporation (NYSE:GKOS) Q1 2026 Earnings Call Transcript - Insider Monkey
Needham raises Glaukos stock price target to $136 on revenue beat - Investing.com
Glaukos wins permanent J-code for Epioxa keratoconus therapy - MSN
BTIG raises Glaukos stock price target to $141 on strong results - Investing.com
Glaukos Corp (GKOS) Q1 2026 Earnings Call Highlights: Record Sal - GuruFocus
Glaukos Announces First Quarter 2026 Financial Results - BioSpace
Glaukos 1Q Loss $19.8M >GKOS - Moomoo
Glaukos (GKOS) Reports Strong Q1 Revenue Growth - GuruFocus
Earnings call transcript: Glaukos Corp beats Q1 2026 forecasts, stock dips By Investing.com - Investing.com Australia
Glaukos (GKOS) Forecasts FY26 Revenue Between $620M and $635M - GuruFocus
Is Glaukos (GKOS) Still 6.0% Undervalued After Q1 Earnings Beat? - GuruFocus
Glaukos (GKOS) posts 41% Q1 revenue growth but remains unprofitable - Stock Titan
Glaukos Up 10% After-Hours After Q1 Earnings Beat - Orange County Business Journal
Vanguard Capital Management takes 5.07% stake in Glaukos (GKOS) via funds and accounts - Stock Titan
Earnings call transcript: Glaukos Corp beats Q1 2026 forecasts, stock dips - Investing.com
Glaukos Corp (NYSE:GKOS) Shares Surge on Record Sales and Raised Guidance After Q1 Beat - ChartMill
Glaukos: Q1 Earnings Snapshot - WKYC
Q1 2026 Glaukos Corp Earnings Call Transcript - GuruFocus
Glaukos (GKOS) Q1 2026 sales jump 41% as guidance lifted to $620–$635M - Stock Titan
Vanguard Portfolio Management (NYSE: GKOS) holds 3.26M shares of Glaukos - Stock Titan
Glaukos earnings ahead as new drug launch tests growth trajectory - Investing.com UK
Glaukos earnings ahead as new drug launch tests growth trajectory By Investing.com - Investing.com South Africa
MSN Money - MSN
Here's Why You Should Retain Glaukos Stock in Your Portfolio - MSN
Glaukos rises as FDA greenlights labeling update for iDose TR - MSN
Glaukos breaks ground on $80M R&D, manufacturing facility in Alabama - MSN
Glaukos gains as Goldman Sachs initiates at Buy on valuation - MSN
Glaukos Corporation (GKOS) Top Loser | Glaukos Corporation misses EPS estimates by 39.9%Stock Analysis Community - Cổng thông tin điện tử tỉnh Lào Cai
GKOS (Glaukos Corporation) posts wider than expected Q4 2025 loss as shares rise 2.61 percent on positive investor sentiment.Core Business Growth - Xã Thanh Hà
Glaukos Receives Permanent J-code for Epioxa, a Treatment for Keratoconus - VisionMonday.com
Is CMS’s Permanent J‑Code for Epioxa Reshaping the Reimbursement Investment Case for Glaukos (GKOS)? - simplywall.st
Glaukos Corp Azioni (GKOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):